CLASS ACTION UPDATE for GSM, WRCDF, CAG and VNDA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, March 17, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
Ferroglobe PLC (NASDAQ: GSM) Class Period: August 21, 2018 - November 26, 2018 Lead Plaintiff Deadline: March 25, 2019 Join the action: https://www.zlk.com/pslra-1/ferroglobe-plc-loss-form?wire=3
The lawsuit alleges: Ferroglobe PLC made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (1) there was excess supply of the Company’s products; (2) demand for the Company’s products was declining; (3) as a result, the pricing of the Company’s products would be materially impacted; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
To learn more about the Ferroglobe PLC class action contact firstname.lastname@example.org.
Wirecard AG (OTCMKTS: WRCDF) Class Period: April 7, 2016 - February 1, 2019 Lead Plaintiff Deadline: April 9, 2019 Join the action: https://www.zlk.com/pslra-1/wirecard-ag-loss-form?wire=3
The lawsuit alleges that, during the class period, Wirecard AG made materially false and/or misleading statements and/or failed to disclose that: (1) for the period spanning from 2015 to 2018, a senior Wirecard executive in Singapore had been accused of forging and backdating contracts, including falsifying accounts and money laundering; (2) an external law firm commissioned to investigate Wirecard’s Singapore office had reportedly found evidence of “serious offences of forgery and/or of falsification of accounts”; (3) Wirecard had downplayed weaknesses in its internal controls over financial reporting and failed to disclose the true extent of those weaknesses; and (4) as a result, defendants’ statements about Wirecard’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the Wirecard AG class action contact email@example.com.
Conagra Brands, Inc. (NYSE: CAG) Class Period: Pursuant to the SPO on or about October 9, 2018 and/or between June 27, 2018 and December 19, 2018 Lead Plaintiff Deadline: April 23, 2019 Join the action: https://www.zlk.com/pslra-1/conagra-brands-inc-loss-form?wire=3
The complaint alleges that defendants failed to disclose material information, including that (i) Conagra inadequately performed proper due diligence in connection with the acquisition of Pinnacle; (ii) the performance of Pinnacle’s three leading brands was not deteriorating due to intensified competition, but to self-inflicted subpar innovation and executional missteps; (iii) Pinnacle’s business was performing so poorly that it had resorted to pushing promotional deals to retailers in an effort to boost sales; and (iv) as a result of the foregoing, Defendant’s public statements were materially false and/or misleading and/or lacked a reasonable basis when made.
To learn more about the Conagra Brands, Inc. class action contact firstname.lastname@example.org.
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) Class Period: November 4, 2015 - February 11, 2019 Lead Plaintiff Deadline: April 26, 2019 Join the action: https://www.zlk.com/pslra-1/vanda-pharmaceuticals-inc-loss-form?wire=3
The lawsuit alleges: Vanda Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Vanda was engaged in a fraudulent scheme in which it promoted the off-label use of Fanapt and Hetlioz; (2) Vanda was fraudulently receiving drug reimbursements from the government by abusing Medicare, Medicaid, and Tricare programs; (3) as a result of the scheme, Vanda faced legal action from the government; (4) Vanda’s promotional materials for Fanapt and Hetlioz were false and misleading, garnering regulatory scrutiny from the U.S. Food and Drug Administration; and (5) as a result, defendants’ statements about Vanda’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the Vanda Pharmaceuticals Inc. class action contact email@example.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.55 Broadway, 10th FloorNew York, NY 10006 firstname.lastname@example.org Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171 www.zlk.com